Equity ImprovementThe improvement in equity indicates a strengthening financial position, which can enhance investor confidence and provide a foundation for future growth initiatives.

Proprietary Technology PlatformsProprietary technology platforms can provide a competitive edge in the biotechnology sector, enabling the development of unique treatments and potential market leadership.

Strategic AlliancesStrategic alliances and collaborations can enhance Altamira's research capabilities, provide financial support, and accelerate the development and commercialization of its therapies.

Bears Say

Negative Cash FlowPersistent negative cash flow can strain the company's liquidity, limiting its ability to invest in growth opportunities and potentially necessitating additional funding.

Declining RevenueDeclining revenue trends suggest challenges in product adoption or market penetration, which could hinder long-term growth and profitability prospects.

Operational InefficienciesOperational inefficiencies and negative profit margins indicate challenges in cost management, which can impact the company's ability to achieve sustainable profitability.

Altamira Therapeutics News

Altamira Therapeutics Reports Progress and Financial Results

Altamira Therapeutics Ltd. ( ($CYTOF) ) has released its Q2 earnings. Here is a breakdown of the information...

6M ago

CYTOF

Altamira Therapeutics Reports Improved Financial Results for Mid-2025

Altamira Therapeutics ( ($CYTOF) ) has provided an update. On August 29, 2025, Altamira Therapeutics released its unaudited...

6M ago

Altamira Therapeutics Announces AGM Results and Board Elections

The latest announcement is out from Altamira Therapeutics ( ($CYTOF) ). On June 11, 2025, Altamira Therapeutics Ltd....

9M ago

Altamira Therapeutics Announces June 2025 Annual General Meeting

Altamira Therapeutics ( ($CYTOF) ) has issued an announcement. Altamira Therapeutics Ltd. announced its upcoming Annual General Meeting...

10M ago

Altamira Therapeutics Reports 2024 Financial Progress

Altamira Therapeutics Ltd. ( ($CYTOF) ) has released its Q4 earnings. Here is a breakdown of the information...

10M ago

CYTOF

Altamira Therapeutics Earnings Call: Growth Amid Challenges

Altamira Therapeutics Ltd. (($CYTOF)) has held its Q4 earnings call. Read on for the main highlights of the...

10M ago

CYTOF

Altamira Therapeutics Announces RNA Delivery Progress and Financial Results

Altamira Therapeutics ( ($CYTOF) ) just unveiled an announcement. On April 30, 2025, Altamira Therapeutics announced significant advancements...

10M ago

Altamira Therapeutics Amends Revenue Sharing Agreement with Altamira Medica

The latest announcement is out from Altamira Therapeutics ( ($CYTOF) ). On March 4, 2025, Altamira Therapeutics Ltd....

12M ago

CYTOF FAQ

What was Altamira Therapeutics’s price range in the past 12 months?

Altamira Therapeutics lowest stock price was $0.05 and its highest was $0.16 in the past 12 months.

What is Altamira Therapeutics’s market cap?

Altamira Therapeutics’s market cap is $542.97K.

When is Altamira Therapeutics’s upcoming earnings report date?

Altamira Therapeutics’s upcoming earnings report date is Apr 15, 2026 which is in 38 days.

How were Altamira Therapeutics’s earnings last quarter?

Altamira Therapeutics released its earnings results on Aug 29, 2025. The company reported -$0.306 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.306.

Is Altamira Therapeutics overvalued?

According to Wall Street analysts Altamira Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Altamira Therapeutics pay dividends?

Altamira Therapeutics does not currently pay dividends.

What is Altamira Therapeutics’s EPS estimate?

Altamira Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Altamira Therapeutics have?

Altamira Therapeutics has 5,715,472 shares outstanding.

What happened to Altamira Therapeutics’s price movement after its last earnings report?

Altamira Therapeutics reported an EPS of -$0.306 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Altamira Therapeutics?

Currently, no hedge funds are holding shares in CYTOF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Altamira Therapeutics

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The firm focuses on the development of intranasal betahistine for the treatment of vertigo and for the prevention of antipsychotic-induced weight gain and somnolence. It also includes other programs under development such as Keyzilen, for the treatment of acute inner ear tinnitus; and Sonsuvi, for the treatment of acute inner ear hearing loss. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.